Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond

Diabetic Medicine : a Journal of the British Diabetic Association
Anthony S Wierzbicki

Abstract

Diabetes is associated with increased cardiovascular disease (CVD) risk. Previous studies with statins have established that a 1 mmol/l reduction in LDL-cholesterol reduces CVD events by 21% over 5 years in people with diabetes. More recently, trials in people with acute coronary syndromes showed that ezetimibe reduced CVD events by 6% at 5 years and achieved a LDL-cholesterol of 1.6 mmol/l with better results in people with Type 2 diabetes. Several novel lipid-lowering therapies have recently been developed. Most data have been accumulated with proprotein convertase subtilisin kexin-9 (PCSK-9) inhibitors, which reduce LDL-cholesterol by 50-55%. A large CVD outcome trial with evolocumab, in which 40% of participants had diabetes, achieved a LDL-cholesterol of 0.8 mmol/l and showed a consistent 20% relative risk reduction within 2 years, including in people with diabetes. Trials to increase HDL-cholesterol using cholesterol ester transfer protein (CETP) inhibitors have generally underwhelmed. Although anacetrapib reduced coronary ischaemic events by 7% in a population with chronic CVD, more expansive CVD endpoints were not improved. The complex nature of CETP inhibitor trial outcomes means that these compounds are not being deve...Continue Reading

References

Apr 4, 1998·The American Journal of Cardiology·S M Grundy
Jul 22, 2005·The New England Journal of Medicine·Christoph WannerUNKNOWN German Diabetes and Dialysis Study Investigators
Apr 20, 2006·International Journal of Clinical Practice·A S Wierzbicki
Dec 1, 2006·The American Journal of Cardiology·Jennifer G Robinson, Neil J Stone
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Apr 5, 2014·Clinical Pharmacology and Therapeutics·R HajhosseinyA S Wierzbicki
Apr 19, 2015·Current Opinion in Lipidology·Bertrand CariouCédric Le May
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Sep 2, 2015·Nature Reviews. Cardiology·Robert S RosensonNancy R Webb
May 4, 2016·The American Journal of Cardiology·Christie M BallantyneNarendra D Lalwani
Jun 2, 2016·Expert Opinion on Biological Therapy·Anthony S Wierzbicki, Adie Viljoen
Nov 29, 2016·Nature Communications·Stephen L PinkoskyNarendra D Lalwani
Dec 3, 2016·The Lancet. Diabetes & Endocrinology·Amand F SchmidtNaveed Sattar
Mar 16, 2017·Clinical Cardiology·Deepak L BhattUNKNOWN REDUCE-IT Investigators
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 18, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN SPIRE Investigators
Mar 18, 2017·The New England Journal of Medicine·Kausik K RayJohn J P Kastelein
Jul 21, 2017·The New England Journal of Medicine·Daniel GaudetG Kees Hovingh
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Aug 30, 2017·The New England Journal of Medicine·UNKNOWN HPS3/TIMI55–REVEAL Collaborative GroupMartin J Landray
Oct 19, 2017·Circulation·Vasanth SathiyakumarSeth S Martin
Nov 25, 2017·Journal of the American College of Cardiology·Mark A Hlatky, Dhruv S Kazi
Dec 9, 2017·Nature Reviews. Disease Primers·Joep C DefescheAnthony S Wierzbicki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

Current Opinion in Cardiology
Anthony S WierzbickiAdie Viljoen
Cardiology Clinics
Angela Pirillo, Alberico L Catapano
Clinical Medicine : Journal of the Royal College of Physicians of London
Anthony S Wierzbicki, Paul Grant
Expert Review of Clinical Pharmacology
T D FilippatosM S Elisaf
© 2022 Meta ULC. All rights reserved